To include your compound in the COVID-19 Resource Center, submit it here.

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III HERMES trial in 1,568 patients showed that that once-daily 500 ug oral Daxas for 52 weeks significantly improved mean pre-bronchodilator FEV1 by 58 mL vs.

Read the full 332 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers